Myokardia Inc.

Address: 1000 Sierra Point Parkway

Sponsor Overview

assignment

Specializations

Hypertrophic cardiomyopathy and obstructive cardiomyopathy

Myokardia Inc. focuses on clinical research in hypertrophic cardiomyopathy, with particular attention to symptomatic obstructive hypertrophic cardiomyopathy and left ventricular outflow tract obstruction. The funded studies examine cardiac symptoms, physical limitation, and exercise capacity in affected adults.

Symptomatic obstructive hypertrophic cardiomyopathy
Left ventricular outflow tract obstruction
Patient-reported health status
Exercise capacity

Research activity also includes imaging-based evaluation of cardiac structure and myocardial thickness in relation to disease burden.

Non-obstructive hypertrophic cardiomyopathy

The sponsor supports trials in non-obstructive hypertrophic cardiomyopathy, addressing both clinical symptoms and longer-term cardiac outcomes. These studies include follow-up research in adults previously enrolled in earlier cardiomyopathy programs.

Non-obstructive hypertrophic cardiomyopathy
Long-term safety and tolerability
Cardiac magnetic resonance imaging
Cardiac mass and structure

Imaging assessments are used to examine changes in ventricular wall thickness and atrial size.

Genetic dilated cardiomyopathy

Myokardia Inc. also funds research in dilated cardiomyopathy linked to inherited variants, including MYH7 and TTN-associated disease. This area reflects interest in cardiomyopathy driven by specific genetic causes and reduced heart function.

MYH7-related dilated cardiomyopathy
TTN-related dilated cardiomyopathy
Genetic heart failure
Reduced cardiac function

Studies in this domain extend to other causal forms of primary dilated cardiomyopathy.

Cardiac myosin-targeted therapy

The sponsor’s research portfolio includes therapies directed at cardiac myosin in adults with cardiomyopathy. Clinical programs evaluate treatment effects across symptomatic disease, structural heart changes, and functional outcomes.

Mavacamten
MYK-224
Danicamtiv
Myocardial structure and function

These studies cover both obstructive and non-obstructive forms of cardiomyopathy, with attention to cardiac remodeling and disease-specific symptom control.

Sponsored Trials

Trial Name	Country	Status
A Long-term Safety Extension Study of Mavacamten (MYK-461) in Adults with Hypertrophic Cardiomyopathy Who Have Completed the MAVERICKHCM (MYK-461-006) or EXPLORER-HCM (MYK-461-005) Trials (MAVA-LTE)	Belgium Czechia Denmark France Germany Italy Poland Portugal Spain The Netherlands	Not Recruiting
Evaluation of Efficacy, Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of BMS-986435 in Symptomatic Obstructive Hypertrophic Cardiomyopathy	Italy Poland Spain	Not Recruiting
Evaluation of Mavacamten in Adults with Symptomatic Non-obstructive Hypertrophic Cardiomyopathy: A Randomized, Double-blind, Placebo-controlled Study	Austria Belgium Czechia Denmark France Germany Hungary Italy Norway Poland Portugal Spain The Netherlands	Not Recruiting
Exploratory Evaluation of Danicamtiv Safety and Efficacy in Ambulatory Patients with Primary Dilated Cardiomyopathy Due to MYH7 or TTN Variants	Germany Spain	Not Recruiting
MEMENTO-A Phase 3b/4 Randomized, Double-blind, Placebo-controlled Clinical Study to Evaluate Mavacamten in Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy to assess the impact on Myocardial Structure with Cardiac Magnetic Resonance Imaging (CMR)	Austria Belgium Czechia Finland France Germany Greece Hungary Italy Poland Spain	Not Yet Recruiting